Filing Flows › Health Care › Viridian Therapeutics (VRDN)
Viridian Therapeutics (VRDN) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Viridian Therapeutics (VRDN) Q3 2026 earnings results →
Q3 2026 Revenue down 64% year over year to $25.8M · 393¢ of every $1 of revenue lost · operating margin -401.8%
Viridian Therapeutics made $25.8M in Q3 2026 (-64% Y/Y): Product revenue, net $24.7M, Collaboration revenue $956K, License revenue $125K. Operating margin -401.8%, net loss $101M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $25.8M in Q3 2026, down 64% year over year and up 8968% from the previous quarter. Product revenue, net was the largest line at 96% of revenue. License revenue lost $69.9M year over year (down 100%), 156% of the total change.
Operating costs exceeded revenue by $103.5M, an operating margin of -401.8%. Total costs grew 17% against a revenue fall of 64%. The fastest-growing cost line was SG&A (+137%). The quarter ended with a net loss of $101.2M, narrower than the previous quarter's $127.1M loss.
Operating cash flow was −$92.8M. Non-cash charges added back $343K of depreciation and amortization and $17.2M of share-based compensation. Working capital and other items used $9.1M. Capital expenditures of $370K exceeded it, leaving free cash flow of −$93.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $25.8M | -64% | -401.8% | −$101M | −$92.8M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $284K | +279% | n/m | −$127M | −$105M |
| Q1 2026 | 10-Q | May 5, 2026 | $141K | +96% | n/m | −$105M | −$120M |
| Q4 2025 | 10-K | Feb 26, 2026 | $132K | +83% | n/m | −$120M | −$23.8M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $70.6M | 821× | -56.7% | −$34.6M | −$84.6M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $75K | +4% | n/m | −$101M | −$75.4M |
| Q1 2025 | 10-Q | May 6, 2025 | $72K | 0% | n/m | −$86.9M | −$92.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Viridian Therapeutics
We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience. We believe there is significant potential in these areas, for better medicines that address unmet needs, improve outcomes, and expand treatment options for patients. We aim to develop differentiated, potential best-in-class medicines that could lead to improved patient outcomes, reduced side effects, improved quality of life, and expanded market access.
In its own words, from its 10-K, filed Feb 26, 2026.
Viridian Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -64% against the peers' median +7%. Operating margin: -401.8% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| VRDN Viridian Therapeutics | Q3 2026 | $25.8M | -64% | -401.8% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Viridian Therapeutics 10-Q on SEC EDGAR · CIK 1590750 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns VRDN and who is buying
More on VRDN
- How Viridian Therapeutics makes money: revenue by segment
- Viridian Therapeutics next earnings date and what analysts expect
- Viridian Therapeutics stock forecast, price target and fair value
- Who owns Viridian Therapeutics stock: holders, funds and Congress trades
- Viridian Therapeutics guidance and outlook
- Viridian Therapeutics recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results